AnaptysBio (NASDAQ:ANAB) Upgraded to “Hold” by BidaskClub

BidaskClub upgraded shares of AnaptysBio (NASDAQ:ANAB) from a sell rating to a hold rating in a research report sent to investors on Friday, BidAskClub reports.

Other equities research analysts have also recently issued reports about the company. Stifel Nicolaus reaffirmed a hold rating on shares of AnaptysBio in a research note on Monday, September 30th. Jefferies Financial Group cut AnaptysBio from a buy rating to a hold rating and set a $12.00 price objective for the company. in a research note on Friday, November 8th. Credit Suisse Group decreased their target price on AnaptysBio from $75.00 to $48.00 and set a neutral rating for the company in a research note on Thursday, October 3rd. Wedbush cut AnaptysBio from an outperform rating to a neutral rating in a research note on Friday, November 8th. Finally, Guggenheim cut AnaptysBio from a buy rating to a neutral rating in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. AnaptysBio presently has a consensus rating of Hold and an average target price of $72.33.

ANAB stock opened at $15.88 on Friday. The company has a market cap of $430.82 million, a P/E ratio of -4.54 and a beta of 1.15. AnaptysBio has a twelve month low of $10.00 and a twelve month high of $83.10. The business has a fifty day moving average of $15.56 and a 200-day moving average of $33.28.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Friday, November 8th. The biotechnology company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.06). During the same period last year, the business earned ($0.66) earnings per share. On average, analysts predict that AnaptysBio will post -4.01 EPS for the current year.

Large investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in AnaptysBio by 42.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,851 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 553 shares during the period. Tower Research Capital LLC TRC acquired a new position in shares of AnaptysBio during the third quarter worth about $66,000. Amundi Pioneer Asset Management Inc. acquired a new position in shares of AnaptysBio during the first quarter worth about $110,000. Bank of Montreal Can acquired a new position in shares of AnaptysBio during the second quarter worth about $115,000. Finally, Whittier Trust Co. boosted its position in shares of AnaptysBio by 35.0% during the third quarter. Whittier Trust Co. now owns 5,085 shares of the biotechnology company’s stock worth $178,000 after buying an additional 1,317 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

Featured Story: Compound Annual Growth Rate (CAGR)

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.